- Home
- PED vs CGTX Comparison
PED vs CGTX Comparison
Compare PED & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PED | CGTX |
|---|---|---|
| Founded | N/A | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.1M | 158.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | PED | CGTX |
|---|---|---|
| Price | $0.57 | $1.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $1.50 | ★ $2.88 |
| AVG Volume (30 Days) | 148.3K | ★ 951.2K |
| Earning Date | 11-17-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 156.43 | N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $33,244,999.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $305.89 | N/A |
| P/E Ratio | $5.34 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.43 | $0.22 |
| 52 Week High | $1.00 | $3.83 |
Technical Indicators
Market Signals| Indicator | PED | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 55.07 | 54.87 |
| Support Level | $0.43 | $1.69 |
| Resistance Level | $0.55 | $1.77 |
| Average True Range (ATR) | 0.04 | 0.13 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 96.81 | 85.25 |
Price Performance
Historical ComparisonAbout PED Pedevco Corp.
PEDEVCO Corp is an oil and gas company focused on oil and natural gas development, exploration, and production. The company focuses on legacy properties where there is a long production history, well-defined geology and existing infrastructure that can be leveraged when applying modern field management technologies. The current properties of the company are located in the San Andres formation of the Permian Basin, situated in West Texas and eastern New Mexico (the Permian Basin), and in the Denver-Julesberg Basin (D-J Basin) in Colorado and Wyoming.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.